1681 studies found for:    "Multiple myeloma"
Show Display Options
Rank Status Study
1 Completed Vaccine Therapy in Treating Patients With Multiple Myeloma
Conditions: Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Refractory Plasma Cell Neoplasm
Interventions: Drug: autologous tumor cell vaccine;   Drug: keyhole limpet hemocyanin;   Drug: melphalan;   Drug: sargramostim
2 Active, not recruiting Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Conditions: Relapsed and Bortezomib Refractory Multiple Myeloma;   Refractory Multiple Myeloma;   Relapsed Multiple Myeloma
Interventions: Drug: panobinostat;   Drug: bortezomib;   Drug: dexamethasone
3 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
4 Active, not recruiting Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: sargramostim;   Biological: aldesleukin;   Other: laboratory biomarker analysis
5 Completed
Has Results
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Intervention: Drug: sunitinib malate
6 Completed Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: vincristine sulfate;   Drug: carmustine;   Drug: melphalan;   Drug: cyclophosphamide;   Drug: prednisone;   Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
7 Completed Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Intervention: Drug: alvocidib
8 Completed Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: temsirolimus;   Other: pharmacological study;   Other: laboratory biomarker analysis
9 Completed Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: temsirolimus;   Other: laboratory biomarker analysis
10 Completed Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Completed Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: plerixafor;   Biological: filgrastim;   Drug: cyclophosphamide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
12 Terminated
Has Results
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: obatoclax mesylate;   Drug: bortezomib;   Other: laboratory biomarker analysis
13 Active, not recruiting Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Waldenström Macroglobulinemia
Intervention: Drug: alvocidib
14 Active, not recruiting Lenalidomide, Dexamethasone and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant For Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: lenalidomide;   Drug: dexamethasone;   Drug: clarithromycin
15 Active, not recruiting Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Conditions: Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: thalidomide;   Drug: dexamethasone
16 Recruiting Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: bortezomib;   Drug: lenalidomide;   Other: laboratory biomarker analysis
17 Active, not recruiting Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: vismodegib;   Other: pharmacological study;   Other: laboratory biomarker analysis
18 Active, not recruiting Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
19 Active, not recruiting Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Biological: recombinant interferon alfa;   Biological: aldesleukin;   Procedure: in vitro-treated peripheral blood stem cell transplantation
20 Active, not recruiting
Has Results
Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: lenalidomide;   Other: placebo;   Procedure: peripheral blood stem cell transplantation;   Drug: melphalan;   Drug: cyclophosphamide;   Biological: filgrastim

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years